{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:36:23Z","timestamp":1779881783276,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40262-023-01287-7","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:01:30Z","timestamp":1690520490000},"page":"1305-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"drks00022547","registry":"10.18810\/drks"}],"author":[{"given":"Amin","family":"Muhareb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-5194","authenticated-orcid":false,"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3537-3205","authenticated-orcid":false,"given":"Andreas D.","family":"Meid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-7181","authenticated-orcid":false,"given":"Kathrin I.","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-0546","authenticated-orcid":false,"given":"Felicitas","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-1698","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-6876","authenticated-orcid":false,"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-133X","authenticated-orcid":false,"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"1287_CR1","unstructured":"Fachinformation. Voriconazol HEXAL\u00ae 50 mg Filmtabletten HA, Germany, October 2016."},{"key":"1287_CR2","unstructured":"World Health Organization. WHO Model List of Essential Medicines. 2019(21)."},{"issue":"1","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","volume":"30","author":"JE Nett","year":"2016","unstructured":"Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin N Am. 2016;30(1):51\u201383.","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.idc.2015.10.015","volume":"30","author":"J Cadena","year":"2016","unstructured":"Cadena J, Thompson GR 3rd, Patterson TF. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin N Am. 2016;30(1):125\u201342.","journal-title":"Infect Dis Clin N Am"},{"issue":"4","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/23744235.2017.1418531","volume":"50","author":"MT Rosanova","year":"2018","unstructured":"Rosanova MT, Bes D, Serrano Aguilar P, Sberna N, Lede R. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis. Infect Dis (Lond). 2018;50(7):489\u201394.","journal-title":"Infect Dis (Lond)."},{"issue":"3","key":"1287_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","volume":"51","author":"J Schulz","year":"2019","unstructured":"Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019;51(3):247\u201365.","journal-title":"Drug Metab Rev"},{"issue":"2","key":"1287_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","volume":"80","author":"G Mikus","year":"2006","unstructured":"Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80(2):126\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1002\/phar.1566","volume":"35","author":"AJ Hsu","year":"2015","unstructured":"Hsu AJ, Dabb A, Arav-Boger R. Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis. Pharmacotherapy. 2015;35(4):e20\u20136.","journal-title":"Pharmacotherapy"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/DHPS.S140213","volume":"9","author":"MJ Ferguson","year":"2017","unstructured":"Ferguson MJ, Randles ML, de Freitas DG. A suspected case of autoinduction of voriconazole metabolism in a patient with cerebral aspergillosis. Drug Healthc Patient Saf. 2017;9:89\u201391.","journal-title":"Drug Healthc Patient Saf."},{"issue":"5","key":"1287_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/0897190018760621","volume":"32","author":"S Farrokh","year":"2019","unstructured":"Farrokh S, Avdic E. Voriconazole autoinduction and saturable metabolism after cessation of rifampin in a patient with invasive central nervous system Aspergillus: importance of therapeutic drug monitoring. J Pharm Pract. 2019;32(5):589\u201394.","journal-title":"J Pharm Pract"},{"issue":"9","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/bcp.13627","volume":"84","author":"B Vreugdenhil","year":"2018","unstructured":"Vreugdenhil B, van der Velden W, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, et al. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol. 2018;84(9):1980\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1287_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.935","volume":"10","author":"N Aiuchi","year":"2022","unstructured":"Aiuchi N, Nakagawa J, Sakuraba H, Takahata T, Kamata K, Saito N, et al. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole. Pharmacol Res Perspect. 2022;10(2): e00935.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"1287_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","volume":"33","author":"A Hassan","year":"2011","unstructured":"Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 2011;33(1):86\u201393.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0091270008327537","volume":"49","author":"J Weiss","year":"2009","unstructured":"Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196\u2013204.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/cpt.1350","volume":"105","author":"G Mikus","year":"2019","unstructured":"Mikus G. Probes and cocktails for drug-drug interaction evaluation: the future is microdosing? Clin Pharmacol Ther. 2019;105(6):1335\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1287_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00228-022-03304-3","volume":"78","author":"A Elbe","year":"2022","unstructured":"Elbe A, Foerster KI, Blank A, Rose P, Burhenne J, Haefeli WE, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975\u201387.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","volume":"12","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016;12(5):479\u201397.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1111\/bcp.14040","volume":"85","author":"N Hohmann","year":"2019","unstructured":"Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol. 2019;85(10):2310\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1287_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jcph.1789","volume":"61","author":"M Mahmoudi","year":"2021","unstructured":"Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J Clin Pharmacol. 2021;61(6):789\u201398.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1287_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bcp.12502","volume":"79","author":"N Hohmann","year":"2015","unstructured":"Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79(2):278\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1287_CR22","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00216-011-5675-y","volume":"402","author":"J Burhenne","year":"2012","unstructured":"Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1\u2032-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402(7):2439\u201350.","journal-title":"Anal Bioanal Chem"},{"issue":"6","key":"1287_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cpt.1529","volume":"106","author":"A Huppertz","year":"2019","unstructured":"Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, Weiss J, et al. Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor voriconazole in healthy volunteers. Clin Pharmacol Ther. 2019;106(6):1290\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1287_CR24","unstructured":"FDA. Guidance for industry: bioanalytical method validation. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 10 Aug 2022."},{"key":"1287_CR25","unstructured":"EMA. Guideline on bioanalytical method validation. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 10 Aug 2022."},{"issue":"3","key":"1287_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/pharmaceutics14030477","volume":"14","author":"J Schulz","year":"2022","unstructured":"Schulz J, Thomas A, Saleh A, Mikus G, Kloft C, Michelet R. Towards the elucidation of the pharmacokinetics of voriconazole: a quantitative characterization of its metabolism. Pharmaceutics. 2022;14(3):477.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1287_CR27","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jphp.12820","volume":"69","author":"MA Hossain","year":"2017","unstructured":"Hossain MA, Tran T, Chen T, Mikus G, Greenblatt DJ. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol. 2017;69(12):1786\u201393.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"1287_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2017","unstructured":"Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45\u201351.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1287_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1287_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1124\/dmd.107.019646","volume":"36","author":"SB Yanni","year":"2008","unstructured":"Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK Jr, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36(6):1119\u201325.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1287_CR31","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1128\/AAC.03820-14","volume":"58","author":"MJ van Wanrooy","year":"2014","unstructured":"van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098\u2013101.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1287_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/dmd.109.029769","volume":"38","author":"SB Yanni","year":"2010","unstructured":"Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38(1):25\u201331.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1287_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.pharmthera.2005.01.001","volume":"106","author":"SK Krueger","year":"2005","unstructured":"Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure\/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106(3):357\u201387.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687\u201393.","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01287-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T08:35:25Z","timestamp":1692866125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01287-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"29 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No conflicts of interest have been declared by any author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial protocol was approved by the responsible ethics committee of the Faculty of Medicine of Heidelberg University (Afmo-431\/2020) and the German competent authority (BfArM) on 13 July 2020 (EudraCT No: 2020-001017-20, registered on March 5th, 2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The collected and analysed data can be made available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all participants included in this trial prior to carrying out any trial procedures.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"G.M. proposed the research topic. A.M., A.B., F.S., G.M. and W.E.H. developed the trial protocol. A.M. and A.B. executed the trial. J.B. and K.I.F. analysed the samples. A.M., G.M. and A.D.M. performed the statistical analyses. A.M. wrote the first draft of the manuscript. All authors discussed and interpreted the results and contributed to the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}